OGIVRI attaches to HER2* receptors on cells. This may stop the cancer cells from growing and multiplying.
Monitor every 3 months in case of significant cardiac dysfunction withhold treatment and monitor every 4 weeks
Monitor every 6 months
(at least for 2 years)
to starting Ogivri
*Normal cells also have HER2, so HER2 targeted therapies like OGIVRI may also affect healthy cells which may cause serious side effects.